Get the Stockscreener App
6.0496
7.08%
0.3996
Ars Pharmaceuticals Inc stock is traded at $6.0496, with a volume of 1.78M.
It is up +7.08% in the last 24 hours and down -13.57% over the past month.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
See More
Previous Close:
$5.65
Open:
$5.62
24h Volume:
1.78M
Relative Volume:
0.86
Market Cap:
$600.16M
Revenue:
$98.99M
Net Income/Loss:
$-197.98M
P/E Ratio:
-3.0222
EPS:
-2.0017
Net Cash Flow:
$-175.32M
1W Performance:
+2.37%
1M Performance:
-13.57%
6M Performance:
-35.50%
1Y Performance:
-58.36%
1-Day Range:
$5.575
$6.11
1-Week Range:
$5.00
$6.19
52-Week Range:
$4.9102
$15.09
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Name
Ars Pharmaceuticals Inc
Sector
Industry
Phone
858-771-9307
Address
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Compare SPRY vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
6.035 | 561.88M | 98.99M | -197.98M | -175.32M | -2.0017 |
VRTX
Vertex Pharmaceuticals Inc
|
515.89 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.79 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.63 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
215.22 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.16 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Northland Capital | Outperform |
| Nov-04-25 | Resumed | Roth Capital | Buy |
| Sep-04-25 | Initiated | Roth Capital | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-10-25 | Initiated | Oppenheimer | Outperform |
| Aug-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-12-24 | Reiterated | Leerink Partners | Outperform |
| Jul-25-24 | Initiated | Raymond James | Outperform |
| Mar-05-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-20-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Initiated | William Blair | Outperform |
| Dec-13-22 | Initiated | SVB Leerink | Outperform |
View All
Ars Pharmaceuticals Inc Stock (SPRY) Latest News
ARS Pharmaceuticals (NASDAQ:SPRY) Trading 5.6% HigherHere's Why - marketbeat.com
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm - lincolnjournal.com
SPRY Investor Alert: ARS Pharmaceuticals Inc. Securities Class Action NoticeContact Levi & Korsinsky - GlobeNewswire
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit - The Conway Daily Sun
2026-08-16 | SPRY DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds ARS Pharmaceuticals Inc. Investors to Join the Class Action Lawsuit Today | NDAQ:SPRY | Press Release - Stockhouse
ARS Pharmaceuticals (SPRY) Stock Faces Margin Squeeze As Losses Deepen - Sahm
Analysts Have Lowered Expectations For ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) After Its Latest Results - simplywall.st
ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure ... - Caledonian Record
ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS - GlobeNewswire
SPRY DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuti - The National Law Review
SPRY Stock Tanks Over 23% After-Hours — ARS Pharmaceuticals Reports No New Major Insurance Wins For Neffy - Stocktwits
Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket - Sahm
SPRY Slides As CVS Caremark Delay Triggers Class Action Hit - timothysykes.com
Cantor Fitzgerald Remains a Buy on ARS Pharmaceuticals (SPRY) - The Globe and Mail
SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
(SPRY) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Down on Disappointing Earnings - marketbeat.com
Attention Long-Term Shareholders of ARS Pharmaceuticals, - GlobeNewswire
ARS Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
ARS Pharmaceuticals Inc (SPRY) (Q2 2026) Earnings Call Highlights: Market Share Doubles to 5% ... By GuruFocus - Investing.com Canada
ARS Pharmaceuticals earnings missed by $0.13, revenue topped estimates - Investing.com Canada
ARS Pharmaceuticals Q2 2026 Earnings Call Transcript - marketbeat.com
ARS Pharmaceuticals Q2 Earnings Call Highlights - marketbeat.com
Kaplan Fox Reminds Investors of ARS Pharmaceuticals Inc. (NASDAQ - The National Law Review
Kaplan Fox Reminds Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to a Securities Class Action DeadlineContact the Firm Before October 5, 2026 - The Globe and Mail
ARS Pharmaceuticals (NASDAQ:SPRY) Posts Earnings Results, Misses Expectations By $0.15 EPS - marketbeat.com
ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results - Investing News Network
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings call transcript: ARS Pharmaceuticals shares fall after Q2 2026 report - Investing.com
ARS Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript - benzinga.com
ARS PHARMACEUTICALS ($SPRY) Releases Q2 2026 Earnings - Quiver Quantitative
ARS Pharma Q2 Results: Revenue up 114% YoY, net loss widens - scanx.trade
ARS Pharmaceuticals (Nasdaq: SPRY) doubles Q2 2026 revenue but posts larger loss - Stock Titan
Did You Lose Money Investing in ARS Pharmaceuticals Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against SPRY - TMX Newsfile
SPRY Deadline Alert: SueWallSt Reminds ARS Pharmaceuticals Inc. (SPRY) Investors of Securities Class Action Deadline on October 5, 2026 - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesSPRY - PR Newswire
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of ARS Pharmaceuticals, Inc. (SPRY) - TMX Newsfile
Hennion & Walsh Asset Management Inc. Acquires Shares of 175,614 ARS Pharmaceuticals, Inc. $SPRY - marketbeat.com
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against ARS Pharmaceuticals, Inc. ... - Caledonian Record
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
SPRY UPCOMING DEADLINE: Levi & Korsinsky Alerts ARS Pharmaceuticals Inc. Stockholders of Securities Class ActionContact the Firm - PR Newswire
What To Expect From ARS Pharmaceuticals Inc (SPRY) Q2 2026 Earnings - Yahoo Finance
What To Expect From ARS Pharmaceuticals Inc (SPRY) Q2 2026 Earni - GuruFocus
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - marketbeat.com
SPRY Investors with Losses in Excess of $100K Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit - Sahm
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm to Learn About Their Legal Rights - Barchart.com
SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ARS Pharmaceuticals Investors Face October Lawsuit Deadline - stl.news
SPRY DEADLINE: The Gross Law Firm Reminds ARS Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline - YCharts
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
Ars Pharmaceuticals Inc Stock (SPRY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ars Pharmaceuticals Inc Stock (SPRY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Karas Eric | Chief Commercial Officer |
Jun 12 '26 |
Sale |
10.00 |
25,000 |
250,000 |
12,176 |
| Fitzpatrick Alexander A | Chief Legal Officer |
Jun 12 '26 |
Sale |
10.00 |
3,355 |
33,550 |
90,910 |
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):